In lymphoma management, which agent is preferred?

In lymphoma management, which agent is preferred?

• A. TNF inhibitors
• B. Rituximab (RTX)
• C. Methotrexate
• D. Leflunomide

Answer: (B)

Rituximab is preferred because it is a monoclonal antibody that targets CD20 on B cells, directly attacking the most common type of lymphoma (B-cell lymphomas) and enhancing the effectiveness of chemotherapy when used in combination (for example with CHOP). This targeted approach improves response rates and survival in many B-cell lymphomas, making it a standard backbone of treatment. The other options aren’t standard lymphoma therapies. TNF inhibitors are used for autoimmune diseases and don’t target malignant B cells. Methotrexate can be used in certain lymphoma contexts (like CNS prophylaxis or specific regimens) but is not the preferred frontline agent for most lymphomas. Leflunomide is a DMARD for rheumatoid conditions and has no role as a lymphoma treatment.

Rituximab is preferred because it is a monoclonal antibody that targets CD20 on B cells, directly attacking the most common type of lymphoma (B-cell lymphomas) and enhancing the effectiveness of chemotherapy when used in combination (for example with CHOP). This targeted approach improves response rates and survival in many B-cell lymphomas, making it a standard backbone of treatment.

The other options aren’t standard lymphoma therapies. TNF inhibitors are used for autoimmune diseases and don’t target malignant B cells. Methotrexate can be used in certain lymphoma contexts (like CNS prophylaxis or specific regimens) but is not the preferred frontline agent for most lymphomas. Leflunomide is a DMARD for rheumatoid conditions and has no role as a lymphoma treatment.